Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 13/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 5/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7759715 | 0.82 | MAPT (0.65) | MAPTNPSR1DRD2EGFRMAPK1 | |
| Trifluoroacetic Acid SCHEMBL6661975 | 0.78 | MAPT (0.57) | MAPTNPSR1DRD2EGFRMAPK1 | |
| SCHEMBL6660597 | 0.76 | MALT1 (0.51) | MAPTNPSR1EGFRMAPK1KMT2A | |
| SCHEMBL6663398 | 0.75 | EGFR (0.48) | MAPTNPSR1EGFRMAPK1KMT2A | |
| SCHEMBL6663857 | 0.74 | EGFR (0.47) | MAPTNPSR1EGFRMAPK1KMT2A | |
| SCHEMBL7060304 | 0.73 | DRD2 (0.48) | MAPTNPSR1DRD2EGFRMAPK1 | |
| SCHEMBL6661677 | 0.73 | MAPT (1.00) | MAPTNPSR1DRD2EGFRMAPK1 | |
| SCHEMBL13519655 | 0.73 | SIGMAR1 (0.42) | DRD2KMT2ALMNAALDH1A1SIGMAR1 | |
| SCHEMBL6666935 | 0.72 | MAPT (0.45) | MAPTNPSR1EGFRMAPK1KMT2A | |
| SCHEMBL6659654 | 0.70 | MAPT (0.46) | MAPTNPSR1DRD2EGFRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | MAPT 4879/4885NPSR1 2757/4885DRD2 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.